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Substance use is a major cause of disability globally. This has been recognized in the recent 
United Nations Sustainable Development Goals (SDGs), in which treatment coverage for 
substance use disorders is identified as one of the indicators. There have been no estimates 
of this treatment coverage cross-nationally, making it difficult to know what is the baseline for 
that SDG target. Here we report data from the World Health Organization (WHO)’s World 
Mental Health Surveys (WMHS), based on representative community household surveys in 
26 countries. We assessed the 12-month prevalence of substance use disorders (alcohol or 
drug abuse/dependence); the proportion of people with these disorders who were aware that 
they needed treatment and who wished to receive care; the proportion of those seeking care 
who received it; and the proportion of such treatment that met minimal standards for 
treatment quality (“minimally adequate treatment”). Among the 70,880 participants, 2.6% met 
12-month criteria for substance use disorders; the prevalence was higher in upper-middle 
income (3.3%) than in high-income (2.6%) and low/lower-middle income (2.0%) countries. 
Overall, 36.5% of those with 12-month substance use disorders recognized a treatment 
need; this recognition was more common in high-income (43.1%) than in upper-middle 
(30.3%) and low/lower-middle income (24.9%) countries. Among those who recognized 
treatment need, 65.7% made at least one visit to a service provider, and 21.8% of the latter 
received minimally adequate treatment exposure (26.3% in high, 13.5% in upper-middle, and 
9.2% in low/lower-middle income countries). Overall, only 5.2% of those with past-year 
substance use disorders received minimally adequate treatment: 7.7% in high income, 2.8% 
in upper-middle income and 1.0% in low/lower-middle income countries. These data suggest 
that only a small minority of people with substance use disorders receive even minimally 
adequate treatment. At least three barriers are involved: awareness/perceived treatment 
need, accessing treatment once a need is recognized, and compliance (on the part of both 
provider and client) to obtain adequate treatment. Various factors are likely to be involved in 
each of these three barriers, all of which need to be addressed to improve treatment 
coverage of substance use disorders. These data provide a baseline for the global 
monitoring of progress of treatment coverage for these disorders as an indicator within the 
SDGs. 
 
Key words: Substance use disorders, alcohol, drugs, treatment coverage, World Health 
Organization, United Nations Sustainable Development Goals 
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Substance use is one of the biggest risk factors for burden of disease globally, 
accounting for 11% of total health burden1. There is increasing recognition of the need for a 
public health rather than a criminal justice approach to substance use disorders2, to reduce 
current burden and prevent future health loss. This is evident in the United Nations’ 
Sustainable Development Goals for 2030, where prevention and treatment of substance use 
disorders feature in the targets3. Two targets are of particular relevance to the current report: 
3.5 - Strengthen prevention and treatment of substance use disorders including opioid use 
and harmful use of alcohol, and 3.8 - Universal health coverage.  
There is considerable concern about barriers to treatment for mental and substance use 
disorders4, and treatment coverage is thought to be far too low globally5. However, few data 
currently exist to shed light specifically on treatment coverage of substance use disorders. 
The World Health Organization (WHO) published its Atlas on Substance Use in 20106, which 
compiled survey responses from member state focal points on levels of service provision for 
treatment of substance use disorders. Responses indicated a low perceived coverage of 
services for people with these disorders6: 40% of participants (in 15 countries) indicated that 
they believed that less than 10% of people with alcohol use disorders received outpatient 
counseling, and 45% of participants (in 95 countries) perceived a similarly low level for drug 
use disorders6, but these reports were based on expert judgments rather than actual data.  
Empirical data have been lacking to date. This paper presents findings from WHO’s 
World Mental Health Surveys (WMHS) on levels of treatment received by people with 
substance use disorders, across countries with varied income and social characteristics, 
examining: a) the 12-month prevalence of DSM-IV substance use disorders in 26 countries 
worldwide; b) the proportion of people with these disorders who recognize a need for 
treatment for their condition; c) the proportion of those with perceived need who receive any 
treatment; and d) the proportion of treatment received that meets minimal standards for 
adequacy (“minimally adequate treatment”).  
 
 
METHODS 
 
Data come from 26 countries participating in the WMHS (N=28 surveys). These 
included 12 countries classified by the World Bank7 as low or middle income (Brazil, 
Bulgaria, Colombia, Iraq, Lebanon, Mexico, Nigeria, People’s Republic of China, Peru, 
Romania, South Africa and Ukraine) and 14 as high income (Argentina, Belgium, France, 
Germany, Israel, Italy, Japan, The Netherlands, New Zealand, Northern Ireland, Poland, 
Portugal, Spain, and the United States). The first study in Colombia (2003) was conducted 
when that country was classified as lower-middle income, while the second (2011-2012) took 
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place when it was classified as upper-middle income. The majority of surveys (N=19) were 
based on nationally representative household samples; three were representative of urban 
areas (Colombia, Mexico, Peru); two were representative of selected regions (Japan, 
Nigeria); and four were representative of selected metropolitan areas (São Paulo in Brazil; 
Medellin in Colombia; Murcia in Spain; Beijing and Shanghai in People’s Republic of China).  
Substance use disorders were assessed using the WHO Composite International 
Diagnostic Interview (CIDI) Version 3.08, a fully-structured lay-administered interview 
generating lifetime and 12-month prevalence estimates of mood, anxiety, behavioural and 
substance use disorders. The interview translation, back-translation and harmonization 
protocol required culturally competent bilingual clinicians to review, modify and approve key 
phrases describing symptoms9. Blinded clinical reappraisal interviews using the Structured 
Clinical Interview for DSM-IV (SCID-I)10 were carried out in four WMHS countries. Good 
concordance was found with diagnoses based on the CIDI11.  
Trained lay assessors administered the interviews face-to-face in the homes of 
participants aged 18 years or older. Standardized interviewer training and quality control 
procedures were used in each survey. Informed consent was obtained before administering 
interviews. Ethics committees of the organizations coordinating the surveys approved the 
procedures for informed consent and protecting human subjects. Full details of the 
methodology are available elsewhere12.   
To reduce participant burden, the interview was divided into two parts. Part 1 was 
administered to all participants and included the core diagnostic assessment of mood and 
anxiety disorders. Part 2 was administered to all respondents with a certain number of mood 
and anxiety symptoms, and to a random proportion of those who had none, and included 
questions about disability and additional mental disorders as well as information on physical 
conditions. Part 2 individuals were weighted by the inverse of their probability of selection to 
adjust for differential sampling, and therefore provide representative data on the target adult 
general population. Further details about sampling and weighting are available elsewhere12.  
Substance use disorders in this paper are defined as meeting past 12-month DSM-IV 
diagnostic criteria for alcohol or drug abuse or dependence. For some countries in the 
earlier-conducted WMHS, a skip existed whereby those who did not endorse any symptoms 
of abuse of a substance were not assessed for dependence. In a separate exercise, we 
imputed data for these countries using data from nine more recently completed surveys 
without the skip pattern. Full details of this process are described elsewhere13.  
Participants with substance use disorders were asked if they had ever received 
treatment for emotional or substance use problems and if they had done so in the past year. 
Those who had received past-year treatment for emotional or substance use problems were 
asked if they had consulted a specialty mental health provider (psychiatrist, psychologist, 
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other mental health professional in any setting, social worker or counsellor in a mental health 
specialty treatment setting, or a mental health hotline); a general provider (primary care 
doctor, other medical doctor, any other health care professional in a general medical 
setting); a non-medical provider (religious or spiritual advisor, social worker or counselor in a 
non-medical setting, any other type of healer); or a self-help group (e.g., alcoholics 
anonymous, narcotics anonymous). The treatment provider categories offered were 
consistent across countries. A more detailed description of WMHS 12-month treatment 
measures is presented elsewhere14.   
The definition of past-year “minimally adequate treatment” focused on the minimum 
number of visits typically required for psychosocial treatments. We assumed that 
pharmacological treatments were less common than psychosocial ones, but questions were 
not included in the survey that allowed us to determine which type of treatment was 
received14. The number of sessions used as the minimally adequate treatment threshold was 
four for people reporting treatment from a specialty mental health or general medical 
provider and six for those receiving treatment from non-medically trained professionals, 
based on evidence from randomized controlled trials15-18. Any participant who was still in 
treatment at the time of interview was regarded as having met this definition, even if he/she 
had not yet had the required number of sessions. 
Participants with substance use disorders were asked if they had ever talked to a 
“medical doctor or other professional (e.g. psychologists, counselors, spiritual advisors, 
herbalists, acupuncturists, and other healing professionals) about their use of 
alcohol/drugs/alcohol or drugs”, and if they had done so in the past year. They were also 
asked if they had attended a self-help group focusing on alcohol or drugs in the past year. 
Those who reported any of these in the past year, and who had had at least the above-
mentioned number of sessions of treatment, or those receiving such treatment at the time of 
interview, were defined as having received “minimally adequate treatment”. 
Since substance use disorders are often comorbid with various mental disorders, we 
also used a broader definition of “minimally adequate treatment”. This included people 
receiving treatment for substance use or emotional problems in the past year for at least the 
above-mentioned number of sessions, or those receiving such treatment at the time of 
interview. 
Survey sampling weights were applied in all analyses to make samples representative 
of target populations in terms of socio-demographic and geographic characteristics. 
Standard errors were estimated using Taylor series linearization implemented in Statistical 
Analysis System (SAS) to account for weighting and clustering19. To test for differences 
between countries; between high, upper-middle and low/lower-middle income country 
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groups; and between countries within each of the three income groups, χ2 tests were 
applied. 
 
 
RESULTS 
 
The characteristics of the study sites are shown in Table 1. The weighted average 
response rate across all surveys was 69.9%. A total of 70,880 participants were assessed 
for substance use disorders. 
Across all countries, 2.6% of participants met 12-month criteria for a DSM-IV substance 
use disorder (Table 2). The prevalence was higher in upper-middle (3.3%) than in high 
(2.6%) and low/lower-middle (2.0%) income countries.  
Across surveys, 36.5% participants with 12-month substance use disorders reported 
that they perceived a need for treatment. Levels of perceived need were higher in high 
(43.1%) than in upper-middle (30.3%) and low/lower-middle (24.9%) income countries.  
Among people with substance use disorders who perceived a need for treatment, 65.7% 
had any contact with a service provider or self-help group in the past year. Again, the 
proportions were much higher in high and upper-middle (67.5% and 69.6% respectively) 
than in low/lower-middle (45.0%) income countries. 
Among people with substance use disorders who received any treatment, 21.8% 
received minimally adequate treatment. Levels were lower in low/lower-middle (9.2%) and 
upper-middle (13.5%) than in high (26.3%) income countries.  
Among all people with substance use disorders, only 5.2% had received at least 
minimally adequate treatment in the past year (7.7%, 2.8% and 1.0%, respectively, in high, 
upper-middle, and low/lower-middle income countries) (Table 2). This was a joint function of 
only around one-third (36.5%) of those with such disorders perceiving that they needed 
treatment; two-thirds of the latter (65.7%) receiving any treatment; and around one in five of 
those with any treatment (21.8%) receiving a level of treatment that was minimally adequate 
(i.e., 0.365 x 0.657 x 0.218 = 5.2%). The two components driving this level down in particular 
were the proportion of people with substance use disorders perceiving a need for treatment 
and the proportion of those receiving any intervention who had a minimally adequate 
exposure to treatment. Nonetheless, it is important to recognize that it is the conjunction of 
all three components being considerably lower than 100% that leads to the very low overall 
prevalence of minimally adequate treatment.  
The differences across all surveys and across country income groups with respect to the 
above variables were all significant at the p<0.0001 level. There were also significant 
differences within each country income group. Exceptions to this included that in low and 
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middle income countries there was no variation in what were very low levels of minimally 
adequate treatment coverage. 
Using the broader definition of minimally adequate treatment, which could have been for 
emotional or substance use problems, estimated levels of minimally adequate treatment 
were around three times higher (see Table 3). Among all people with past-year substance 
use disorders, using this broader definition, 14.1% had received minimally adequate 
treatment in the past year (20.5%, 7.7% and 3.6%, respectively, in high, upper-middle and 
low/lower-middle income countries).  
 
 
DISCUSSION 
 
Substance use disorders are prevalent in many countries, yet there have been no 
estimates of treatment coverage for these disorders cross-nationally. We found that, even 
using a definition of minimally adequate treatment that required relatively low levels of 
treatment exposure, coverage was extremely low: one in 13 people with these disorders in 
high income countries, one in 36 people in upper-middle income countries, and only one 
percent of people in low/lower-middle income countries. Few countries, even in high income 
settings, had high coverage of minimally adequate treatment. 
Several limitations of our study need to be considered. There might be differential social, 
religious and legal contexts across countries that affected willingness to report substance 
use. Several strategies were used to maximize the likelihood of honest reporting. First, pilot 
testing was carried out to determine the best way to describe the study in order to increase 
willingness to respond honestly and accurately. Second, in countries that do not have a 
tradition of public research, and where concepts of anonymity and confidentiality are less 
familiar, community leaders were contacted to explain the study and obtain formal 
endorsement; these leaders announced the study and encouraged participation. Third, 
interviewers were centrally trained in use of non-directive probing, which is designed to 
encourage thoughtful, honest responding. Finally, especially sensitive questions were asked 
in a self-report rather than an interviewer-report format (among those who could read). 
These strategies were probably not effective in removing all cross-national differences in 
willingness to report, and remaining differences that could have contributed to reporting 
biases should be borne in mind. Nonetheless, the cross-national variations we found in the 
prevalence of substance use disorders are consistent with other global and country-level 
reports on substance use epidemiology20-23.  
We focused on psychosocial treatments, and did not include pharmacotherapies. 
However, although there is good evidence for the efficacy and effectiveness of opioid 
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substitution therapy for opioid dependence24,25, the evidence concerning other substance 
use disorders is less compelling. Evidence is mixed as regards pharmacotherapies for 
cannabis dependence26 and lacking for psychostimulant dependence27-29. Medications for 
alcohol dependence (by far the most prevalent substance use disorder), such as naltrexone, 
have evidence of efficacy30, but uptake and adherence are very low.  
The available information suggests that pharmacotherapies may be even less frequently 
utilized to treat substance use disorders than psychosocial interventions we included here. 
For example, a systematic review found that only 8 per 100 people who inject drugs received 
opioid substitution therapy in the previous year31. In Australia, only around 0.5% of alcohol 
dependent people are estimated to have been prescribed naltrexone or acamprosate for the 
recommended 3-month duration32.  
We have not examined the role of comorbid disorders in affecting recognition of 
treatment need and access to services. This is not really a limitation of our study, in that we 
were prima ily interested in treatment coverage among all people with substance use 
disorders. It is nonetheless important to acknowledge that these people, when they have 
additional mental disorders, may seek treatment for those other disorders, presumably 
increasing the likelihood of recognition of substance use disorders and the relevant 
treatment need. 
The data we presented here are on self-reported service use. WMHS attempted to 
minimize inaccuracies in self-report by using commitment probes (i.e., questions measuring 
a subject’s commitment to the survey), and excluding respondents who did not endorse such 
probes. Without studies that involve linkage to routine administrative or facility-based 
datasets on substance use treatment, there is no viable alternative. In many countries no 
such study designs are yet feasible, particularly in those with more limited infrastructure, due 
to both clinical and technological reasons. 
Some surveys were conducted over a decade ago, raising the possibility that treatment 
rates in the relevant countries have changed since. We consider this unlikely, since more 
recent data on service provision collected for the WHO Atlas on Substance Use6, and as 
part of the work of the Reference Group to the United Nations on HIV and Injecting Drug 
Use31, similarly revealed very low perceived6 and actual31 coverage of services.  
Response rates in the WMHS varied widely. We attempted to control for differential 
response through post-stratification adjustments, but it remains possible that survey 
response was related to the presence and severity of substance use disorders or treatment 
in ways that were not corrected. Having said that, existing evidence suggests that household 
and community-based surveys produce underestimates of problematic substance use for a 
number of reasons20,33,34, suggesting that the estimates of prevalence reported here are 
conservative, and estimates of coverage potentially higher than actual levels.  
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The issue of perceived need for treatment is important. Even if treatment were easily 
available to all people with substance use disorders, our findings suggest that only one in 
three across countries would feel they need help, with slightly lower levels in low income 
settings. This strongly indicates that efforts to improve treatment coverage for substance use 
disorders will need to address both scaling up of services as well as supporting people with 
these disorders to recognize need for help and seek treatment. The latter is challenging, and 
complex public health interventions may be required that increase recognition of and 
willingness to address the problem among those living with these disorders, as well as their 
family and community.  
Even among those who recognized the problem, a significant proportion did not access 
any services. This is likely to be the result of a complex array of individual, social and 
structural level barriers to seeking help. These include treatment availability, awareness of 
and access to effective treatment35, fear of stigma (from family and community), financial 
barriers in contexts where treatment must be paid for by the individual, as well as legal, 
policy, service and even law-enforcement barriers to people with substance use disorders 
being able to access services36-39. 
Treatment access per se is not sufficient. There is a need to ensure treatment quality, 
which includes delivery of effective interventions in sufficient doses. There may be 
alternative methods of defining minimally adequate treatment within the constraints of the 
WMHS measure. It is clear, however, that most people needing treatment did not receive a 
minimally adequate level, even though our definition involved a relatively small number of 
service contacts. Overall, only one in 20 people with substance use disorders were receiving 
minimally adequate treatment.  
Quality improvement initiatives, such as adoption of the evidence-based WHO Mental 
Health Gap Action Programme (mhGAP) Intervention Guide40-42 and work of the United 
Nations Office for Drug and Crime and the WHO in improving treatment quality in low and 
middle income countries (Treatnet)43,44 are important efforts in this regard. However, 
significant investment in service systems and capacity building will need to occur in countries 
that currently have little to no formal treatment services or where substance use disorders 
are addressed outside of the health system. 
Improving treatment coverage will hence require action at several levels: low rates of 
recognition of treatment need by people with substance use disorders, low rates of 
consultation by people who do recognize that they have a problem, and finally, inadequate 
treatment exposure when it is received. There is a need to act across all these levels to 
improve the coverage and quality of treatment for people with these disorders.  
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CONCLUSIONS  
 
The United Nations Sustainable Development Goals reflect political commitment to 
scale up treatment coverage of substance use disorders. We have presented unique person-
level data on services use by people with these disorders cross-nationally, demonstrating 
very low treatment coverage. This is true across country income levels, but worryingly, 
lowest in lower income countries, which also include the greatest share of the world’s 
population.  
Access to services is not the only barrier. A combination of limited recognition of 
treatment need, barriers to accessing treatment, and inadequacy of treatments delivered are 
all responsible for this low coverage.  
These data might be considered as a baseline measure of this key sustainable 
development goal (and indeed for the WHO’s Mental Health Action Plan 2013-2020, which 
aims to increase service coverage for severe mental disorders by 20% by the year 202045). 
Given how poor current coverage is, it seems clear that substantial efforts across the above 
levels are needed to achieve the goal set by the United Nations for the year 2030. Regular 
review of this coverage indicator will be crucial. 
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Table 1   World Mental Health Surveys: characteristics of the samples 
 
Country Sampling  
 
Field dates 
 
Age range Sample size Response rate 
    Part 1 Part 2 
Part 2 and 
age ≤44 
 
 
Low and lower-middle income countries 
Colombia 
 
All  urban areas of the country (about 73% of the total national 
population)  2003 18-65 4,426 2,381 1,731 87.7% 
Iraq Nationally representative 2006-7 18-96 4,332 4,332 − 95.2% 
Nigeria 
 
21 of the 36 states in the country (about 57% of the national 
population)  2002-4 18-100 6,752 2,143 1,203 79.3% 
China Beijing and Shanghai metropolitan areas 2001-3 18-70 5,201 1,628 570 74.7% 
Peru All  urban areas of the country 2004-5 18-65 3,930 1,801 1,287 90.2% 
Ukraine Nationally representative 2002 18-91 4,725 1,720 541 78.3% 
Total    29,366 14,005 5,332 82.8% 
Upper-middle income countries 
Brazil  São Paulo metropolitan area 2005-8 18-93 5,037 2,942 − 81.3% 
Bulgaria Nationally representative 2002-6 18-98 5,318 2,233 741 72.0% 
Colombia Medellin metropolitan area 2011-12 19-65 3,261 1,673 − 97.2% 
Lebanon Nationally representative 2002-3 18-94 2,857 1,031 595 70.0% 
Mexico 
 
All  urban areas of the country (about 75% of the total national 
population).  
2001-2 18-65 5,782 2,362 1,736 76.6% 
Romania Nationally representative 2005-6 18-96 2,357 2,357 − 70.9% 
South Africa Nationally representative 2002-4 18-92 4,315 4,315 − 87.1% 
Total    28,927 16,913 3,072 78.5% 
High income countries 
Argentina Nationally representative 2015 18-98 3,927 2,116 − 77.3% 
Belgium Nationally representative 2001-2 18-95 2,419 1,043 486 50.6% 
France Nationally representative  2001-2 18-97 2,894 1,436 727 45.9% 
Germany Nationally representative  2002-3 19-95 3,555 1,323 621 57.8% 
Israel Nationally representative 2003-4 21-98 4,859 4,859 − 72.6% 
Italy Nationally representative 2001-2 18-100 4,712 1,779 853 71.3% 
Japan Eleven metropolitan areas  2002-6 20-98 4,129 1,682 − 55.1% 
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The Netherlands Nationally representative 2002-3 18-95 2,372 1,094 516 56.4% 
New Zealand Nationally representative 2004-5 18-98 12,790 7,312 − 73.3% 
North Ireland Nationally representative 2005-8 18-97 4,340 1,986 − 68.4% 
Poland Nationally representative 2010-11 18-65 10,081 4,000 2,276 50.4% 
Portugal Nationally representative 2008-9 18-81 3,849 2,060 1,070 57.3% 
Spain Nationally representative 2001-2 18-98 5,473 2,121 960 78.6% 
Spain Murcia region  2010-12 18-96 2,621 1,459 − 67.4% 
United States Nationally representative 2001-3 18-99 9,282 5,692 3,197 70.9% 
Total    77,303 39,962 10,706 63.5% 
 
Overall sample    
 
135,596 
 
70,880 
 
19,110 
 
69.9% 
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Table 2  12-month prevalence (% and standard error) of substance use disorders, perceived need for treatment, receipt of any treatment, and receipt of minimally 
adequate treatment 
 
  12-month 
diagnosis of 
substance use 
disorders 
Perceived need for 
treatment among 
those with substance 
use disorders 
Any 12-month 
treatment among 
those with perceived 
need  
Minimally adequate 
treatment among 
those with any 
treatment  
Minimally adequate 
treatment among all 
those with substance 
use disorders 
  
Low and lower-middle income 
          
N  
Colombia 2.9±0.4 42.7±5.9 18.8±6.5 12.8±4.0 1.0±0.9 90 
Iraq 0.2±0.1 61.5 84.7 0.0  0.0 7 
Nigeria 0.9±0.2 21.3±5.5 95.4±0.1 0.0  0.0  37 
Peru 2.3±0.4 44.2±5.8 26.5±4.3 20.0 2.3±1.8 50 
China (Beijing/Shanghai) 1.7±0.4 8.1±1.2 100.0  0.0  0.0 52 
Ukraine 6.6±0.8 8.3±1.8 100.0±0.0 13.3±6.4 1.1±0.8 153 
Total 2.0±0.2 24.9±2.0 45.0±4.0 9.2±2.1 1.0±0.5 389 
Upper-middle income 
          
  
Brazil  (São Paulo) 3.8±0.4 38.0±5.0 51.0±7.4 24.8±9.1 4.8±2.4 164 
Bulgaria 1.2±0.3 12.9±6.0 30.6 59.6 2.4±0.2 39 
Lebanon 1.3±0.8 11.4±0.5 100.0 43.0 4.9±0.2 12 
Colombia (Medellin) 4.1±0.6 31.3±5.9 37.8±11.7 8.2±8.6 1.0±1.0 85 
Mexico 2.6±0.4 41.0±3.9 45.3±3.1 8.6±0.1 1.6±1.3 80 
Romania 1.0±0.2 14.0±8.7 72.8 100.0  10.2±8.0 20 
South Africa 5.8±0.6 28.3±3.9 100.0±0.0 7.2±0.5 2.0±1.0 214 
Total 3.3±0.2 30.3±2.2 69.6±3.0 13.5±2.0 2.8±0.8 614 
High income             
Argentina 2.4±0.3 37.1±5.8 59.5±4.6 12.2±4.9 2.7±1.2 73 
Belgium 2.7±0.8 28.7±4.1 66.4±8.1 35.8±16.5 6.8±1.5 30 
France 1.5±0.3 44.4±9.2 75.9±9.1 32.5±14.8 10.9±6.4 31 
Germany 1.6±0.5 12.8±0.8 63.5±25.5 100.0  8.2±3.0 25 
Israel 1.4±0.2 23.8±4.4 54.9±5.8 10.6±0.8 1.4±1.4 70 
Italy 0.4±0.1 27.2±9.2 58.1  0.0 0.0 11 
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Japan 1.0±0.2 29.5±4.2 55.5±9.4 0.0 0.0 29 
The Netherlands 1.8±0.4 28.3±6.7 81.4±0.1 18.0±0.1 4.2±0.9 32 
New Zealand 3.7±0.3 51.4±2.7 66.0±2.8 26.1±3.1 8.9±1.6 474 
Northern Ireland 3.5±0.5 50.6±3.8 85.3±2.0 11.9±3.9 5.1±1.9 68 
Poland 3.6±0.3 24.9±4.1 62.8±3.2 38.5±3.4 6.0±1.8 181 
Portugal 1.6±0.3 35.5±8.0 77.7±8.4 13.5±2.5 3.7±0.4 40 
Spain 1.1±0.3 13.3±2.9 78.8±17.3 44.7±1.8 4.7 ±1.1 25 
Spain (Murcia) 1.0±0.4 53.6  78.2  47.1  19.8  17 
United States 4.2±0.4 59.9±2.6 66.1±2.8 29.9±4.0 11.8±1.8 314 
Total 2.6±0.1 43.1±1.4 67.5±1.4 26.3±1.8 7.7±0.7 1,420 
Overall sample 2.6±0.1 36.5±1.1 65.7±1.3 21.8±1.3 5.2±0.5 2,423 
Chi-square tests             
Across all  surveys (χ2, df=27) 727.2 (p<0.0001) 254.9 (p<0.0001) 97.0 (p<0.0001) 42.9 (p<0.0001) 70.3 (p<0.0001)   
Across country income groups (χ2, df=2) 50.2 (p<0.0001) 58.6 (p<0.0001) 52.8 (p<0.0001) 16.1 (p<0.0001) 33.3 (p<0.0001)   
Across high income countries (χ2, df=14) 254.2 (p<0.0001) 127.1 (p<0.0001) 15.6 (p=0.0014) 17.6 (p<0.0001) 23.9 (p<0.0001)   
Across upper-middle income countries 
(χ2, df=6) 176.4 (p<0.0001) 17.8 (p=0.0084) 3.3 (p=0.2109) 9.9 (p<0.0001) 9.1 (p=0.0822)   
Across low/lower-middle income 
countries (χ2, df=5) 271.8 (p<0.0001) 67.0 (p<0.0001) 25.5 (p<0.0001) 0.3 (p=0.5696) 0.5 (p=0.6945)   
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Table 3  12-month prevalence (% and standard error) of receipt of minimally adequate treatment using a broader definition including people who required treatment 
for substance use or emotional problems  
 
 
  Minimally adequate treatment 
among those with any 
treatment 
Minimally adequate treatment 
among all those with substance 
use disorders  
  
Low and lower-middle income 
  
 
  
N  
Colombia 47.2±11.2 3.8±1.7  90 
Iraq 17.2  9.0 7 
Nigeria 0.0  0.0  37 
Peru 42.9  5.0±2.5  50 
China (Beijing/Shanghai) 50.4  4.1±1.0 52 
Ukraine 36.3±9.9  3.0±1.3  153 
Total 32.3±3.6  3.6±0.8  389 
Upper-middle income 
    
  
Brazil  (São Paulo) 51.3±5.0  9.9±2.6  164 
Bulgaria 59.6  2.4±0.2  39 
Lebanon 66.3  7.6±0.3  12 
Colombia (Medellin) 78.6±5.6  9.3±3.5  85 
Mexico 23.7±0.4  4.4±1.4  80 
Romania 100.0 10.2±8.0  20 
South Africa 26.0±3.4  7.4±1.8  214 
Total 36.4±2.3 7.7±1.1  614 
High income       
Argentina 77.6±6.7  17.1±4.7  73 
Belgium 57.9±22.7  11.1±2.1  30 
France 67.8±5.5  22.8±5.6  31 
Germany 100.0  8.2±3.0 25 
Israel 80.0±5.2  10.5±3.2  70 
Italy 53.2  8.4±1.2 11 
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Japan 80.5  13.1±2.7 29 
The Netherlands 61.6±0.3  14.2±3.1 32 
New Zealand 68.5±2.5  23.3±2.0  474 
Northern Ireland 58.2±9.4  25.1±4.8  68 
Poland 71.8±2.8  11.2±2.4  181 
Portugal 81.7±8.7  22.5±6.5  40 
Spain 92.9±6.8  9.7±4.4 25 
Spain (Murcia) 47.1  19.8 17 
United States 74.9±4.4  29.6±3.0  314 
Total 70.6±2.1  20.5±1.2  1,420 
Overall sample 58.9±1.7  14.1±0.8  2,423 
Chi-square tests       
Across all  surveys (χ2, df=27) 102.6 (p<0.0001) 159.2 (p<0.0001)   
Across country income groups (χ2, df=2) 72.2 (p<0.0001) 98.0 (p<0.0001)   
Across high income countries (χ2, df=14) 12.2 (p=0.0324) 46.8 (p<0.0001)   
Across upper-middle income countries 
(χ2, df=6) 14.6 (p<0.0001) 3.6 (p=0.5474)   
Across low/lower-middle income 
countries (χ2, df=5) 2.3 (p=0.0399) 1.5 (p=0.4990)   
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